Search

Your search keyword '"Huang, Hui-Yao"' showing total 38 results
Start Over Author "Huang, Hui-Yao"
38 results on '"Huang, Hui-Yao"'

2. Integrating China in the International Consortium for Personalised Medicine. A position Paper on Personalised Medicine in Sustainable Healthcare

Author

Causio, Francesco Andrea, primary, Beccia, Flavia, additional, Hoxhaj, Ilda, additional, Huang, Hui-Yao, additional, Wang, Lily, additional, Wang, Wenya, additional, Farina, Sara, additional, Osti, Tommaso, additional, Savoia, Cosimo, additional, Cadeddu, Chiara, additional, Ricciardi, Walter, additional, and Boccia, Stefania, additional

Published
2023
Full Text
View/download PDF

3. Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey

Author

Zhang, Xin, Shi, Ju-Fang, Liu, Guo-Xiang, Ren, Jian-Song, Guo, Lan-Wei, Huang, Wei-Dong, Shi, Lin-Mei, Ma, Yi, Huang, Hui-Yao, Bai, Ya-Na, Liao, Xian-Zhen, Mao, A-Yan, Sun, Xiao-Jie, Zhu, Xin-Yu, Zhou, Qi, Gong, Ji-Yong, Zhou, Jin-Yi, Liu, Yu-Qin, Mai, Ling, Song, Bing-Bing, Zhu, Lin, Xing, Xiao-Jing, Du, Ling-Bin, Qi, Xiao, Sun, Xiao-Hua, Wu, Shou-Ling, Ren, Ying, Cao, Rong, Lan, Li, Lou, Pei-An, Zhang, Kai, He, Jie, and Dai, Min

Published
2021
Full Text
View/download PDF

5. Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey

Author

Wang, Le, Shi, Ju-Fang, Zhu, Juan, Huang, Hui-Yao, Bai, Ya-Na, Liu, Guo-Xiang, Liao, Xian-Zhen, Mao, A-Yan, Ren, Jian-Song, Sun, Xiao-Jie, Guo, Lan-Wei, Fang, Yi, Zhou, Qi, Ma, Heng-Min, Xing, Xiao-Jing, Zhu, Lin, Song, Bing-Bing, Du, Ling-Bin, Mai, Ling, Liu, Yu-Qin, Ren, Ying, Lan, Li, Zhou, Jin-Yi, Qi, Xiao, Sun, Xiao-Hua, Lou, Pei-An, Wu, Shou-Ling, Li, Ni, Zhang, Kai, He, Jie, and Dai, Min

Published
2018
Full Text
View/download PDF

6. Integrating China in the International Consortium for Personalized Medicine: A Position Paper on Personalized Medicine in Sustainable Healthcare.

Author

Causio, Francesco Andrea, Beccia, Flavia, Hoxhaj, Ilda, Huang, Hui-Yao, Wang, Lily, Wang, Wenya, Farina, Sara, Osti, Tommaso, Savoia, Cosimo, Cadeddu, Chiara, Ricciardi, Walter, and Boccia, Stefania

Subjects
INDIVIDUALIZED medicine, CONSORTIA, PREVENTIVE medicine, MEDICAL care, SUSTAINABILITY, CLINICAL medicine
Abstract

Introduction: Over the last decade, the emergence and spread of personalized medicine (PM) have defined a substantial revolution in healthcare. In principle, healthcare system sustainability is challenged by the investments required for research and development, as well as the adoption of PM techniques in routine clinical care. The "Integrating China in the International Consortium for Personalized Medicine" (IC2PerMed) EU-funded project aims to integrate China into the "International Consortium for Personalized Medicine" (ICPerMed). IC2PerMed aims to align the EU and China's research agendas in this field to enable a swift development of approaches in the EU and China with strong leverage upon EU-Chinese collaborations. Methods: Within this project, we first mapped relevant policies on PM in both the EU and China, and then we involved European and Chinese experts in PM in workshops and Delphi surveys in order to identify relevant priorities for the implementation of PM in sustainable healthcare. Results: As a result of this process, we identified nine overarching priorities, each addressing specific aspects of the sustainability of healthcare systems and PM implementation, with the main goal of supporting policymakers in integrating PM approaches in the EU and China. Discussion/conclusion: The implementation of PM in health systems is appealing in terms of improved accuracy in diagnostics, treatment, and prevention of disease, as well as reduction of the side effects resulting from inefficient use of drugs. Research, development, and implementation of needed techniques require time and resources that can slow the adoption of PM in healthcare systems. The nine priorities we identified address some of the most critical points, trying to lay the foundations for a comprehensive approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Integrating China in the international consortium for personalised medicine. a position paper on healthcare professionals’ education and citizens’ empowerment in personalised medicine

Author

Beccia, Flavia, Causio, Francesco Andrea, Hoxhaj, Ilda, Huang, Hui-Yao, Wang, Lily, Wang, Wenya, Farina, Sara, Osti, Tommaso, Savoia, Cosimo, Cadeddu, Chiara, Ricciardi, Walter, Boccia, Stefania, Cadeddu, Chiara (ORCID:0000-0003-0149-1078), Ricciardi, Walter (ORCID:0000-0002-5655-688X), Boccia, Stefania (ORCID:0000-0002-1864-749X), Beccia, Flavia, Causio, Francesco Andrea, Hoxhaj, Ilda, Huang, Hui-Yao, Wang, Lily, Wang, Wenya, Farina, Sara, Osti, Tommaso, Savoia, Cosimo, Cadeddu, Chiara, Ricciardi, Walter, Boccia, Stefania, Cadeddu, Chiara (ORCID:0000-0003-0149-1078), Ricciardi, Walter (ORCID:0000-0002-5655-688X), and Boccia, Stefania (ORCID:0000-0002-1864-749X)

Abstract

BackgroundPersonalised medicine (PM) has been fostered by technological and medical advances, but all stakeholders, including healthcare professionals, citizens and policy makers, should achieve adequate health literacy to promote PM implementation. The "Integrating China in the International Consortium for Personalised Medicine" (IC2PerMed) project, funded by the International Consortium for Personalised Medicine, focuses on this issue by highlighting the need to educate healthcare professionals and empower citizens. Within the aforementioned project, building on a mapping of European and Chinese policies in PM, experts in the field of PM participated in an online workshop and a following two-round Delphi survey, in order to identify the priority areas of intervention for healthcare professionals' education and curricula, engagement and empowerment of citizens and patients.ResultsNine experts completed the survey and reached a consensus on seventeen priorities: seven were related to health professionals' education and curricula, whereas ten on citizen and patients' awareness and empowerment.ConclusionThese priorities emphasized the importance of education and health literacy, multidisciplinary and international collaboration, public trust, and consideration of ethical, legal, and social issues. The present experience highlights the relevance of the involvement of stakeholders in informing decision-makers, developing appropriate national plans, strategies, and policies, and ensuring the adequate implementation of PM in health systems.

Published
2023

9. Medical expenses of urban Chinese patients with stomach cancer during 2002–2011: a hospital-based multicenter retrospective study

Author

Sun, Xiao-Jie, Shi, Ju-Fang, Guo, Lan-Wei, Huang, Hui-Yao, Yao, Neng-Liang, Gong, Ji-Yong, Sun, Ya-Wen, Liu, Guo-Xiang, Mao, A-Yan, Liao, Xian-Zhen, Bai, Ya-Na, Ren, Jian-Song, Zhu, Xin-Yu, Zhou, Jin-Yi, Mai, Ling, Song, Bing-Bing, Liu, Yu-Qin, Zhu, Lin, Du, Ling-Bin, Zhou, Qi, Xing, Xiao-Jing, Lou, Pei-An, Sun, Xiao-Hua, Qi, Xiao, Wang, Yuanzheng, Cao, Rong, Ren, Ying, Lan, Li, Zhang, Kai, He, Jie, Wang, Jia-Lin, Dai, Min, and The listed authors are on behalf of the Health Economic Evaluation Working Group, Cancer Screening Program in Urban China (CanSPUC)

Published
2018
Full Text
View/download PDF

11. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours

Author

Wang, Shuhang, primary, Huang, Hui-Yao, additional, Wu, Dawei, additional, Fang, Hong, additional, Ying, Jianming, additional, Bai, Ying, additional, Yu, Yue, additional, Fang, Yuan, additional, Jiang, Ning, additional, Sun, Chao, additional, Yu, Anqi, additional, Fan, Qi, additional, Xing, Shujun, additional, Ni, Yufen, additional, Zhang, Wei, additional, Wu, Chenhua, additional, Ji, Xinqian, additional, Wang, Hui, additional, Guo, Yaqian, additional, Tang, Qiyu, additional, Wang, Yuan, additional, Tang, Yu, additional, and Li, Ning, additional

Published
2021
Full Text
View/download PDF

12. Clinical development of immuno-oncology in China

Author

Wu, Da-Wei, Huang, Hui-Yao, Tang, Yu, Zhao, Yang, Yang, Zhi-Min, Wang, Jun, Wang, Shu-Hang, Yu, Yue, Fang, Yuan, Fang, Hong, Bai, Ying, Sun, Chao, Fan, Qi, Yu, An-Qi, Wang, Huan-Ling, Du, Chun-Xia, Chen, Kun, Huang, Ming-De, Zhang, Yin, Li, Ning, Xu, Bing-He, Sun, Yan, and He, Jie

Published
2020
Full Text
View/download PDF

13. Availability of anticancer biosimilars in 40 countries

Author

Huang, Hui-Yao, Wu, Da-Wei, Ma, Fei, Liu, Zhi-Lei, Shi, Ju-Fang, Chen, Xia, Wang, Shu-Hang, Fang, Hong, Bai, Ying, Yu, Yue, Fang, Yuan, Sun, Chao, Fan, Qi, Wu, Ying, Fan, Rui-Hua, Zhou, Cai-Yun, He, Bao-Xia, Dai, Min, Li, Ning, Xu, Bing-He, Sun, Yan, and He, Jie

Published
2020
Full Text
View/download PDF

14. Medical expenditure for liver cancer in urban China: A 10-year multicenter retrospective survey (2002-2011)

Author

Qiu, Wu-Qi, Shi, Ju-Fang, Guo, Lan-Wei, Mao, A-Yan, Huang, Hui-Yao, Hu, Guang-Yu, Dong, Pei, Bai, Fang-Zhou, Yan, Xiao-Ling, Liao, Xian-Zhen, Liu, Guo-Xiang, Bai, Ya-Na, Ren, Jian-Song, Sun, Xiao-Jie, Zhu, Xin-Yu, Zhou, Jin-Yi, Gong, Ji-Yong, Zhu, Lin, Mai, Ling, Du, Ling-Bing, Zhou, Qi, Xing, Xiao-Jing, Song, Bing-Bing, Liu, Yu-Qin, Lou, Pei-An, Sun, Xiao-Hua, Wu, Shou-Ling, Cao, Rong, Qi, Xiao, Lan, Li, Ren, Ying, Zhang, Kai, He, Jie, Qu, Chunfeng, and Dai, Min

Subjects
Liver cancer -- Surveys -- Care and treatment -- Diagnosis, Medical records -- Usage, Health
Abstract

Byline: Wu-Qi. Qiu, Ju-Fang. Shi, Lan-Wei. Guo, A-Yan. Mao, Hui-Yao. Huang, Guang-Yu. Hu, Pei. Dong, Fang-Zhou. Bai, Xiao-Ling. Yan, Xian-Zhen. Liao, Guo-Xiang. Liu, Ya-Na. Bai, Jian-Song. Ren, Xiao-Jie. Sun, Xin-Yu. [...]

Published
2018

15. Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review

Author

Huang, Hui-Yao, primary, Liu, Cheng-Cheng, additional, Yu, Yue, additional, Wang, Le, additional, Wu, Da-Wei, additional, Guo, Lan-Wei, additional, Wang, Shu-Hang, additional, Fang, Hong, additional, Bai, Ying, additional, Fang, Yuan, additional, Fan, Qi, additional, Sun, Chao, additional, Wu, Ying, additional, Shi, Ju-Fang, additional, Ma, Fei, additional, Tang, Yu, additional, Dai, Min, additional, and Li, Ning, additional

Published
2020
Full Text
View/download PDF

16. Health‐related quality of life of patients with colorectal neoplasms in China: A multicenter cross‐sectional survey

Author

Huang, Hui‐Yao, primary, Wang, Hong, additional, Shi, Ju‐Fang, additional, Bai, Ya‐Na, additional, Wang, Le, additional, Liu, Cheng‐Cheng, additional, Yan, Xin‐Xin, additional, Liu, Guo‐Xiang, additional, Liao, Xian‐Zhen, additional, Shi, Dian, additional, Mao, A‐Yan, additional, Ren, Jian‐Song, additional, Sun, Xiao‐Jie, additional, Guan, Hai‐Jing, additional, Huang, Wei‐Dong, additional, Lei, Hai‐Ke, additional, Gong, Ji‐Yong, additional, Liu, Yun‐Yong, additional, Zhu, Lin, additional, Song, Bing‐Bing, additional, Du, Lin‐Bing, additional, Guo, Lan‐Wei, additional, Liu, Yu‐Qin, additional, Ren, Ying, additional, Lan, Li, additional, Zhou, Jin‐Yi, additional, Qi, Xiao, additional, Sun, Xiao‐Hua, additional, Lou, Pei‐An, additional, Wu, Shou‐Ling, additional, Tang, Yu, additional, Li, Ni, additional, Zhang, Kai, additional, Li, Ning, additional, Chen, Wan‐Qing, additional, Dai, Min, additional, and He, Jie, additional

Published
2020
Full Text
View/download PDF

19. Epidemiological and economic evaluation of breast cancer screening in urban population in China: a multitarget calibrated modelling study

Author

Wang, Le, primary, Shi, Ju-Fang, additional, Li, Qing-Na, additional, Zhu, Juan, additional, Wang, Zhong-Zhao, additional, Li, Jing, additional, Yin, Juan, additional, Huang, Hui-Yao, additional, Bai, Fang-Zhou, additional, Ren, Jian-Song, additional, Fang, Yi, additional, Bai, Ya-Na, additional, Liao, Xian-Zhen, additional, Li, Ni, additional, Li, Bing-Zhao, additional, Chen, Wan-Qing, additional, and Dai, Min, additional

Published
2019
Full Text
View/download PDF

20. Short‐term impact of breast cancer screening intervention on health‐related quality of life in China: A multicentre cross‐sectional survey

Author

Zhu, Juan, primary, Wang, Le, additional, Huang, Hui‐Yao, additional, Bai, Fang‐Zhou, additional, Li, Jing, additional, Fang, Yi, additional, Wang, Yong, additional, Mao, A‐Yan, additional, Liao, Xian‐Zhen, additional, Liu, Guo‐Xiang, additional, Bai, Ya‐Na, additional, Ren, Jian‐Song, additional, Sun, Xiao‐Jie, additional, Guo, Lan‐Wei, additional, Wang, De‐Bin, additional, Dong, Heng‐Jin, additional, Wang, Jia‐Lin, additional, Xing, Xiao‐Jing, additional, Zhou, Qi, additional, Zhu, Lin, additional, Du, Ling‐Bin, additional, Song, Bing‐Bing, additional, Luo, Su‐Xia, additional, Liu, Yu‐Qin, additional, Ren, Ying, additional, Zhou, Jin‐Yi, additional, Sun, Xiao‐Hua, additional, Lan, Li, additional, Wu, Shou‐Ling, additional, Qi, Xiao, additional, Lou, Pei‐An, additional, Ma, Fei, additional, Li, Ni, additional, Zhang, Kai, additional, Chen, Wan‐Qing, additional, He, Jie, additional, Dai, Min, additional, and Shi, Ju‐Fang, additional

Published
2019
Full Text
View/download PDF

21. Economic burden of lung cancer attributable to smoking in China in 2015

Author

Shi, Ju-Fang, primary, Liu, Cheng-Cheng, additional, Ren, Jian-Song, additional, Parascandola, Mark, additional, Zheng, Rong, additional, Tang, Wei, additional, Huang, Hui-Yao, additional, Li, Fang, additional, Wang, Le, additional, Su, Kai, additional, Li, Ni, additional, Zhang, Kai, additional, Chen, Wan-Qing, additional, Wu, Ning, additional, Zou, Xiao-Nong, additional, Liu, Guo-Xiang, additional, and Dai, Min, additional

Published
2019
Full Text
View/download PDF

22. Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey

Author

Shi, Ju-Fang, primary, Wang, Le, additional, Wu, Ning, additional, Li, Jun-Ling, additional, Hui, Zhou-Guang, additional, Liu, Shang-Mei, additional, Yang, Bo-Yan, additional, Gao, Shu-Geng, additional, Ren, Jian-Song, additional, Huang, Hui-Yao, additional, Zhu, Juan, additional, Liu, Cheng-Cheng, additional, Fan, Jin-Hu, additional, Zhao, Shi-Jun, additional, Xing, Pu-Yuan, additional, Zhang, Ye, additional, Li, Ning, additional, Lei, Wen-Dong, additional, Wang, De-Bin, additional, Huang, Yun-Chao, additional, Liao, Xian-Zhen, additional, Xing, Xiao-Jing, additional, Du, Ling-Bin, additional, Yang, Li, additional, Liu, Yu-Qin, additional, Zhang, Yong-Zhen, additional, Zhang, Kai, additional, Qiao, You-Lin, additional, He, Jie, additional, and Dai, Min, additional

Published
2019
Full Text
View/download PDF

23. Health‐related quality of life of patients with colorectal neoplasms in China: A multicenter cross‐sectional survey.

Author

Huang, Hui‐Yao, Wang, Hong, Shi, Ju‐Fang, Bai, Ya‐Na, Wang, Le, Liu, Cheng‐Cheng, Yan, Xin‐Xin, Liu, Guo‐Xiang, Liao, Xian‐Zhen, Shi, Dian, Mao, A‐Yan, Ren, Jian‐Song, Sun, Xiao‐Jie, Guan, Hai‐Jing, Huang, Wei‐Dong, Lei, Hai‐Ke, Gong, Ji‐Yong, Liu, Yun‐Yong, Zhu, Lin, and Song, Bing‐Bing

Subjects
*QUALITY of life, *CHINESE people, *CANCER pain, *TUMORS, *PRECANCEROUS conditions
Abstract

Background and Aim: This study aimed to clarify health‐related quality of life (HRQoL) of patients with colorectal precancer and colorectal cancer (CRC) in China and to better understand related utility scores. Methods: A hospital‐based cross‐sectional survey was conducted in precancer and CRC patients from 2012 to 2014, covering 12 provinces in China. HRQoL was assessed with EuroQol 5‐Dimensions 3‐Levels. Utility scores were derived using Chinese value set. A multivariate regression model was established to explore potential predictors of utility scores. Results: A total of 376 precancer (mean age 58.7 years, 61.2% men) and 2470 CRC patients (mean age 58.6 years, 57.6% men) were included. In five dimensions, there was a certain percentage of problem reported among precancer (range: 12.0% to 36.7%) and CRC (range: 32.4% to 50.3%) patients, with pain/discomfort being the most serious dimension. Utility scores of precancer and CRC patients were 0.870 (95% confidence interval [CI], 0.855–0.886) and 0.751 (95% CI, 0.742–0.759), both of which were lower than those of general Chinese population (0.960 [95% CI, 0.960–0.960]). Utilities for patients at stage I to stage IV were 0.742 (95% CI, 0.715–0.769), 0.722 (95% CI, 0.705–0.740), 0.756 (95% CI, 0.741–0.772), and 0.745 (95% CI, 0.742–0.767), respectively. Multivariate analysis showed that therapeutic regimen, time point of the interview, education, occupation, annual household income, and geographic region were associated with utilities of CRC patients. Conclusion: Health‐related quality of life of both precancer and CRC patients in China declined considerably. Utility scores differed by sociodemographic and clinical characteristics, and findings of these utilities may facilitate implementation of further cost–utility evaluations. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Medical expenditure for liver cancer in urban China: A 10-year multicenter retrospective survey (2002–2011)

Author

Shi, Ju-Fang, primary, Mao, A-Yan, primary, Qiu, Wu-Qi, additional, Guo, Lan-Wei, additional, Huang, Hui-Yao, additional, Hu, Guang-Yu, additional, Dong, Pei, additional, Bai, Fang-Zhou, additional, Yan, Xiao-Ling, additional, Liao, Xian-Zhen, additional, Liu, Guo-Xiang, additional, Bai, Ya-Na, additional, Ren, Jian-Song, additional, Sun, Xiao-Jie, additional, Zhu, Xin-Yu, additional, Zhou, Jin-Yi, additional, Gong, Ji-Yong, additional, Zhu, Lin, additional, Mai, Ling, additional, Du, Ling-Bing, additional, Zhou, Qi, additional, Xing, Xiao-Jing, additional, Song, Bing-Bing, additional, Liu, Yu-Qin, additional, Lou, Pei-An, additional, Sun, Xiao-Hua, additional, Wu, Shou-Ling, additional, Cao, Rong, additional, Qi, Xiao, additional, Lan, Li, additional, Ren, Ying, additional, Zhang, Kai, additional, He, Jie, additional, Qu, Chunfeng, additional, and Dai, Min, additional

Published
2018
Full Text
View/download PDF

26. Sustainability of cancer screening in China: a multicentre assessment from the perspective of service suppliers and demanders

Author

Shi, Ju-Fang, primary, Mao, A-Yan, additional, Sun, Zong-Xiang, additional, Dong, Pei, additional, Huang, Hui-Yao, additional, Qiu, Wu-Qi, additional, Lei, Hai-Ke, additional, Liu, Guo-Xiang, additional, Wang, De-Bin, additional, Bai, Ya-Na, additional, Sun, Xiao-Jie, additional, Liao, Xian-Zhen, additional, Ren, Jian-Song, additional, Guo, Lan-Wei, additional, Wang, Le, additional, Li, Jiang, additional, Lan, Li, additional, Zhou, Qi, additional, Song, Bing-Bing, additional, Yang, Li, additional, Du, Ling-Bin, additional, Zhou, Jin-Yi, additional, Zhu, Lin, additional, Wang, Jia-Lin, additional, Mai, Ling, additional, Liu, Yu-Qin, additional, Liu, Yun-Yong, additional, Zhang, Yong-Zhen, additional, Wu, Shou-Ling, additional, Zhang, Kai, additional, He, Jie, additional, and Dai, Min, additional

Published
2017
Full Text
View/download PDF

27. Trends on clinical characteristics and medical service use of lung cancer in China 2005–14: a multicentre retrospective survey

Author

Wang, Le, primary, Shi, Ju-Fang, additional, Wu, Ning, additional, Li, Jun-Ling, additional, Hui, Zhou-Guang, additional, Liu, Shang-Mei, additional, Yang, Bo-Yan, additional, Gao, Shu-Geng, additional, Ren, Jian-Song, additional, Huang, Hui-Yao, additional, Zhu, Juan, additional, Wang, De-Bin, additional, Huang, Yun-Chao, additional, Liao, Xian-Zhen, additional, Xing, Xiao-Jing, additional, Du, Ling-Bin, additional, Yang, Li, additional, Liu, Yu-Qin, additional, Zhang, Yong-Zhen, additional, Zhang, Kai, additional, Qiao, You-Lin, additional, He, Jie, additional, and Dai, Min, additional

Published
2017
Full Text
View/download PDF

28. WITHDRAWN: Medical expenditure for liver cancer in urban China: a 10-year multicenter retrospective survey (2002-2011)

Author

Qiu, Wu-Qi, primary, Shi, Ju-fang, additional, Guo, Lan-Wei, additional, Mao, A-Yan, additional, Huang, Hui-Yao, additional, Hu, Guang-Yu, additional, Dong, Pei, additional, Yan, Xiao-Ling, additional, Liao, Xian-Zhen, additional, Liu, Guo-Xiang, additional, Bai, Ya-Na, additional, Ren, Jian-Song, additional, Sun, Xiao-Jie, additional, Zhu, Xin-Yu, additional, Zhou, Jin-Yi, additional, Gong, Ji-Yong, additional, Zhu, Lin, additional, Mai, Ling, additional, Zhou, Qi, additional, Xing, Xiao-Jing, additional, Song, Bing-Bing, additional, Du, Ling-Bing, additional, Lou, Pei-An, additional, Sun, Xiao-Hua, additional, Wu, Shou-Ling, additional, Liu, Yu-Qin, additional, Cao, Rong, additional, Qi, Xiao, additional, Lan, Li, additional, Ren, Ying, additional, Zhang, Kai, additional, He, Jie, additional, Qu, Chen-feng, additional, and Dai, Min, additional

Published
2017
Full Text
View/download PDF

29. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey

Author

Huang, Hui-Yao, primary, Shi, Ju-Fang, additional, Guo, Lan-Wei, additional, Bai, Ya-Na, additional, Liao, Xian-Zhen, additional, Liu, Guo-Xiang, additional, Mao, A-Yan, additional, Ren, Jian-Song, additional, Sun, Xiao-Jie, additional, Zhu, Xin-Yu, additional, Wang, Le, additional, Song, Bing-Bing, additional, Du, Ling-Bin, additional, Zhu, Lin, additional, Gong, Ji-Yong, additional, Zhou, Qi, additional, Liu, Yu-Qin, additional, Cao, Rong, additional, Mai, Ling, additional, Lan, Li, additional, Sun, Xiao-Hua, additional, Ren, Ying, additional, Zhou, Jin-Yi, additional, Wang, Yuan-Zheng, additional, Qi, Xiao, additional, Lou, Pei-An, additional, Shi, Dian, additional, Li, Ni, additional, Zhang, Kai, additional, He, Jie, additional, and Dai, Min, additional

Published
2017
Full Text
View/download PDF

30. Economic burden of lung cancer attributable to smoking in China in 2015

Author

Shi, Ju-Fang, Liu, Cheng-Cheng, Ren, Jian-Song, Parascandola, Mark, Zheng, Rong, Tang, Wei, Huang, Hui-Yao, Li, Fang, Wang, Le, Su, Kai, Li, Ni, Zhang, Kai, Chen, Wan-Qing, Wu, Ning, Zou, Xiao-Nong, Liu, Guo-Xiang, and Dai, Min

Abstract

BackgroundLung cancer is substantially attributable to smoking, but detailed related estimates on smoking-attributable expenditure (SAE) in China are not available yet, which could inform tobacco control and cancer prevention initiatives.MethodsA prevalence-based approach was adopted to estimate the total SAE, including direct expenditure (medical and non-medical) and indirect cost (disability and premature death). Detailed per-patient data on direct expenditure and work-loss days were acquired from a unique multicentre survey in China. Other parameters were from literatures and official reports.ResultsThe total estimated SAE of lung cancer was US$5249 million in China in 2015 (0.05 % of gross domestic product for China). The estimated direct SAE was US$1937 million (36.9 % of the total SAE), accounting for 0.29 % of total healthcare expenditure for China. The medical and non-medical direct expenditures were US$1749 million and US$188 million, respectively. The estimated indirect cost was US$3312 million (63.1 % of the total SAE), including US$377 million due to disability and US$2935 million due to premature death. The SAE increased with age, peaking at 60–64 years (US$1004 million), and was higher among men, in urban areas and in eastern China. If smoking prevalence was reduced to 20%, as is the goal of Healthy China 2030, the total SAE would be decreased by 4.9 %.ConclusionsSmoking-attributable economic burden caused by lung cancer was substantial in China in 2015, and will continue increasing given current trends in lung cancer. However, future economic burden can be prevented with implementation of effective tobacco control and other interventions.

Published
2020
Full Text
View/download PDF

31. Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study

Author

Huang, Hui-Yao, primary, Shi, Ju-Fang, additional, Guo, Lan-Wei, additional, Zhu, Xin-Yu, additional, Wang, Le, additional, Liao, Xian-Zhen, additional, Liu, Guo-Xiang, additional, Bai, Ya-Na, additional, Mao, A-Yan, additional, Ren, Jian-Song, additional, Sun, Xiao-Jie, additional, Zhang, Kai, additional, He, Jie, additional, and Dai, Min, additional

Published
2016
Full Text
View/download PDF

32. Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey

Author

Shi, Ju-Fang, primary, Huang, Hui-Yao, additional, Guo, Lan-Wei, additional, Shi, Dian, additional, Gu, Xiu-Ying, additional, Liang, Han, additional, Wang, Le, additional, Ren, Jian-Song, additional, Bai, Ya-Na, additional, Mao, A-Yan, additional, Liu, Guo-Xiang, additional, Liao, Xian-Zhen, additional, Zhang, Kai, additional, He, Jie, additional, and Dai, Min, additional

Published
2016
Full Text
View/download PDF

33. Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross-sectional study.

Author

Liao, Xian‐Zhen, Shi, Ju‐Fang, Liu, Jing‐Shi, Huang, Hui‐Yao, Guo, Lan‐Wei, Zhu, Xin‐Yu, Xiao, Hai‐Fan, Wang, Le, Bai, Ya‐Na, Liu, Guo‐Xiang, Mao, A‐Yan, Ren, Jian‐Song, Sun, Xiao‐Jie, Mai, Ling, Liu, Yu‐Qin, Song, Bing‐Bing, Gong, Ji‐Yong, Zhou, Jin‐Yi, Du, Ling‐Bing, and Zhou, Qi

Subjects
BREAST cancer diagnosis, BREAST cancer treatment, MEDICAL care costs, HEALTH surveys, MEDICARE reimbursement
Abstract

Aim: We aimed to assess economic burden of breast cancer (BC) diagnosis and treatment in China through a multicenter cross-sectional study, and to obtain theoretical evidence for policy-making. Methods: This survey was conducted in 37 hospital centers across 13 provinces in China from September 2012 to December 2014. We collected information on the subject characteristics. We then assessed the medical and non-medical expenditure for BC diagnosis and treatment, factors influencing the average case expense, variations between medical and non-medical expenditure at different clinical stages, economic impact of overall expenditure in newly diagnosed course after reimbursement to the patient's family, composition of non-medical expenditure and time loss for the patient and family. Results: Among 2746 women with BC (72.6% were admitted to specialized hospitals), the overall average expenditure was US $8450 (medical expenditure: $7527; non-medical expenditure: $922). Significant differences were found among the overall expenditure in the four clinical stages (P<0.0001); the expenditure was higher in stages III and IV than that in stages I and II, whereas the stage IV was the highest (P < 0.0001). Moreover, a higher self-reported predicted reimbursement ratio was associated with a less economic impact on the patient's family, and the average time lost was estimated as $1529. Conclusions: Early detection and treatment of breast cancer might be effective for decreasing the economic burden, because costs escalate as the degree of malignancy increases. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

35. WITHDRAWN: Medical expenditure for liver cancer in urban China: a 10-year multicenter retrospective survey (2002-2011)

Author

Qiu, Wu-Qi, Shi, Ju-fang, Guo, Lan-Wei, Mao, A-Yan, Huang, Hui-Yao, Hu, Guang-Yu, Dong, Pei, Yan, Xiao-Ling, Liao, Xian-Zhen, Liu, Guo-Xiang, Bai, Ya-Na, Ren, Jian-Song, Sun, Xiao-Jie, Zhu, Xin-Yu, Zhou, Jin-Yi, Gong, Ji-Yong, Zhu, Lin, Mai, Ling, Zhou, Qi, Xing, Xiao-Jing, Song, Bing-Bing, Du, Ling-Bing, Lou, Pei-An, Sun, Xiao-Hua, Wu, Shou-Ling, Liu, Yu-Qin, Cao, Rong, Qi, Xiao, Lan, Li, Ren, Ying, Zhang, Kai, He, Jie, Qu, Chen-feng, and Dai, Min

Full Text
View/download PDF

36. Integrating China in the international consortium for personalised medicine. a position paper on healthcare professionals' education and citizens' empowerment in personalised medicine.

Author

Beccia F, Causio FA, Hoxhaj I, Huang HY, Wang L, Wang W, Farina S, Osti T, Savoia C, Cadeddu C, Ricciardi W, and Boccia S

Subjects
Humans, Educational Status, China, Delivery of Health Care, Precision Medicine, Curriculum
Abstract

Background: Personalised medicine (PM) has been fostered by technological and medical advances, but all stakeholders, including healthcare professionals, citizens and policy makers, should achieve adequate health literacy to promote PM implementation. The "Integrating China in the International Consortium for Personalised Medicine" (IC2PerMed) project, funded by the International Consortium for Personalised Medicine, focuses on this issue by highlighting the need to educate healthcare professionals and empower citizens. Within the aforementioned project, building on a mapping of European and Chinese policies in PM, experts in the field of PM participated in an online workshop and a following two-round Delphi survey, in order to identify the priority areas of intervention for healthcare professionals' education and curricula, engagement and empowerment of citizens and patients., Results: Nine experts completed the survey and reached a consensus on seventeen priorities: seven were related to health professionals' education and curricula, whereas ten on citizen and patients' awareness and empowerment., Conclusion: These priorities emphasized the importance of education and health literacy, multidisciplinary and international collaboration, public trust, and consideration of ethical, legal, and social issues. The present experience highlights the relevance of the involvement of stakeholders in informing decision-makers, developing appropriate national plans, strategies, and policies, and ensuring the adequate implementation of PM in health systems., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

37. Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross-sectional study.

Author

Liao XZ, Shi JF, Liu JS, Huang HY, Guo LW, Zhu XY, Xiao HF, Wang L, Bai YN, Liu GX, Mao AY, Ren JS, Sun XJ, Mai L, Liu YQ, Song BB, Gong JY, Zhou JY, Du LB, Zhou Q, Cao R, Zhu L, Ren Y, Lou PA, Lan L, Sun XH, Qi X, Wang YZ, Zhang K, He J, and Dai M

Subjects
China, Costs and Cost Analysis, Cross-Sectional Studies, Female, Health Expenditures, Humans, Middle Aged, Surveys and Questionnaires, Breast Neoplasms diagnosis, Breast Neoplasms economics, Breast Neoplasms pathology, Breast Neoplasms therapy
Abstract

Aim: We aimed to assess economic burden of breast cancer (BC) diagnosis and treatment in China through a multicenter cross-sectional study, and to obtain theoretical evidence for policy-making., Methods: This survey was conducted in 37 hospital centers across 13 provinces in China from September 2012 to December 2014. We collected information on the subject characteristics. We then assessed the medical and non-medical expenditure for BC diagnosis and treatment, factors influencing the average case expense, variations between medical and non-medical expenditure at different clinical stages, economic impact of overall expenditure in newly diagnosed course after reimbursement to the patient's family, composition of non-medical expenditure and time loss for the patient and family., Results: Among 2746 women with BC (72.6% were admitted to specialized hospitals), the overall average expenditure was US $8450 (medical expenditure: $7527; non-medical expenditure: $922). Significant differences were found among the overall expenditure in the four clinical stages (P < 0.0001); the expenditure was higher in stages III and IV than that in stages I and II, whereas the stage IV was the highest (P < 0.0001). Moreover, a higher self-reported predicted reimbursement ratio was associated with a less economic impact on the patient's family, and the average time lost was estimated as $1529., Conclusions: Early detection and treatment of breast cancer might be effective for decreasing the economic burden, because costs escalate as the degree of malignancy increases., (© 2017 John Wiley & Sons Australia, Ltd.)

Published
2018
Full Text
View/download PDF

38. Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002-2011).

Author

Guo LW, Huang HY, Shi JF, Lv LH, Bai YN, Mao AY, Liao XZ, Liu GX, Ren JS, Sun XJ, Zhu XY, Zhou JY, Gong JY, Zhou Q, Zhu L, Liu YQ, Song BB, Du LB, Xing XJ, Lou PA, Sun XH, Qi X, Wu SL, Cao R, Lan L, Ren Y, Zhang K, He J, Zhang JG, and Dai M

Subjects
Aged, China, Female, Humans, Male, Middle Aged, Retrospective Studies, Time Factors, Esophageal Neoplasms economics
Abstract

Background: Esophageal cancer is associated with substantial disease burden in China, and data on the economic burden are fundamental for setting priorities in cancer interventions. The medical expenditure for the diagnosis and treatment of esophageal cancer in China has not been fully quantified. This study aimed to examine the medical expenditure of Chinese patients with esophageal cancer and the associated trends., Methods: From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 37 hospitals in 13 provinces/municipalities across China as a part of the Cancer Screening Program of Urban China. For each esophageal cancer patient diagnosed between 2002 and 2011, clinical information and expense data were extracted by using structured questionnaires. All expense data were reported in Chinese Yuan (CNY; 1 CNY = 0.155 USD) based on the 2011 value and inflated using the year-specific health care consumer price index for China., Results: A total of 14,967 esophageal cancer patients were included in the analysis. It was estimated that the overall average expenditure per patient was 38,666 CNY, and an average annual increase of 6.27% was observed from 2002 (25,111 CNY) to 2011 (46,124 CNY). The average expenditures were 34,460 CNY for stage I, 39,302 CNY for stage II, 40,353 CNY for stage III, and 37,432 CNY for stage IV diseases (P < 0.01). The expenditure also differed by the therapy type, which was 38,492 CNY for surgery, 27,933 CNY for radiotherapy, and 27,805 CNY for chemotherapy (P < 0.05). Drugs contributed to 45.02% of the overall expenditure., Conclusions: These conservative estimates suggested that medical expenditures for esophageal cancer in China substantially increased in the last 10 years, treatment for early-stage esophageal cancer costs less than that for advanced cases, and spending on drugs continued to account for a considerable proportion of the overall expenditure.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results